While not quite a cure for the common cold, Johnson & Johnson spinout PrEP Biopharm certainly intends to transform the cold and flu market with its prophylactic drug.
The startup’s developing a weekly nasal spray that arms the innate immune system against cold- and flu-causing viruses – and is raising $25 million to do so. Advertisement
The startup just formed about three months ago, as a spinout of Johnson & Johnson – and aims to now raise a $25 million Series A.
Help employers find you! Check out all the jobs and post your resume.
The startup’s developing a weekly nasal spray that arms the innate immune system against cold- and flu-causing viruses – and is raising $25 million to do so. Advertisement
The startup just formed about three months ago, as a spinout of Johnson & Johnson – and aims to now raise a $25 million Series A.
Help employers find you! Check out all the jobs and post your resume.
